New-DES vs BMS in SVG -1 Year Outcomes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

792 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-02-01

Study Completion Date

2020-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Data regarding the efficacy of the percutaneous coronary intervention (PCI) with new-designed drug-eluting stent (new-DES) vs. bare metal stent (BMS) of saphenous vein grafts (SVG) stenosis is scarce. The primary objective was to compare one-year clinical outcomes of PCI in stenosis of SVG using new-DES vs. BMS in a real-world population. We carried out a multi-center registry comparing new-DES with BMS in all consecutive patients undergoing PCI of SVG. The primary composite endpoint was major adverse cardiac and cerebrovascular events (MACCE) at 1 year.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

DEB vs Thin-DES in DES-ISR: Long Term Outcomes (DEB Dragon Registry)

NCT04415216

In Stent Restenosis

COMPLETED

Bioabsorbable Versus Durable Polymer Drug Eluting Stent (DES): a Meta-analysis

NCT01466634

Restenosis Myocardial Infarction

COMPLETED

A Randomized Comparison of Clinical Outcomes Between Everolimus-eluting Bioresorbable Vascular Scaffold Versus Everolimus-eluting Metallic Stent in Long Coronary Lesions

NCT02796157

Coronary Artery Disease

UNKNOWN NA

Treatment of Coronary Artery Disease (CAD) With Bare Metal Stent (BMS) Followed by Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Eluting Stent

NCT01166711

Coronary Artery Disease

COMPLETED NA

DEB Versus 2nd Generation DES in Patients With In-Scaffold Restenosis of Bioresorbable Vascular Scaffold

NCT03074305

Coronary Artery Disease Coronary Restenosis

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SVG PCI

new-DES

Intervention Type DEVICE

with ot without embolic protection device

BMS

Intervention Type DEVICE

with ot without embolic protection device

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

new-DES

with ot without embolic protection device

Intervention Type DEVICE

BMS

with ot without embolic protection device

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients after CABG with significant SVG stenosis referred for PCI

Exclusion Criteria

* patients who had both types of stents implanted in the same procedure
* patients with the old-DES
* patients who had PCI of other vascular territories during the same procedure

Eligible Sex

ALL

Accepts Healthy Volunteers

No